drug

TC-5619

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Targacept Inc.
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia
NCT01488929Phase 2Completed
TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia
NCT01003379Phase 2Completed

KOLs & investigators

2
David P Walling, PhDKOL score 17
Jeffrey A. Lieberman, MDKOL score 9

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Targacept Inc.
company
trial
Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia
PHASE2
trial
TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia
PHASE2
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Cognitive Dysfunction
indication
Cognitive Dysfunction
indication
KOL
David P Walling, PhD
KOL score 17
person
Jeffrey A. Lieberman, MD
KOL score 9
person